AstraZeneca's pill camizestrant, to be marketed as Etcamah, secured an accelerated OK from the FDA. That decision arrived even after the FDA's Oncology Drugs Advisory Committee voted it down earlier this year. In announcing the approval on Friday, the agency said it gives women with breast cancer another way to treat the disease.
Etcamah can be taken with other cancer medicines by patients with a genetically driven form of metastatic breast cancer. It is aimed at people whose tumors carry a particular mutation that can arise during endocrine therapy. Patients must first confirm that mutation using an FDA-authorized test before starting Etcamah. By cutting off estrogen's ability to activate tumor cells, the treatment curbs their proliferation.
When headlines grab attention, steady investing often wins over time, so download the free Always Be Buying E-Book
AstraZeneca has presented evidence that the pill lengthens the period before the disease gets worse by more than six months. On the revenue side, the company says Etcamah could eventually top $5 billion a year, while analysts surveyed by Bloomberg peg 2032 sales at nearly $2.3 billion. CEO Pascal Soriot has already steered multiple cancer blockbusters to market, and the company is leaning on its oncology pipeline for continued growth while lining up to compete in weight loss therapies. For everyday investors, that combo of a fresh approval, tempered Street forecasts, and a busy pipeline is the kind of setup that can shape how a big pharma story unfolds over the next few years.
